<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33451">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01866319</url>
  </required_header>
  <id_info>
    <org_study_id>3475-006</org_study_id>
    <secondary_id>2012-004907-10</secondary_id>
    <nct_id>NCT01866319</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)</brief_title>
  <official_title>A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a three-arm study to evaluate the safety and efficacy of two dosing schedules of
      pembrolizumab (MK-3475) compared to ipilimumab for the treatment of ipilimumab-na√Øve
      participants with unresectable or metastatic melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">645</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab Every 2 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab, 10 mg intravenously (IV), once every 2 weeks for up to 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab Every 3 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab, 10 mg IV, once every 3 weeks for up to 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipilimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive ipilimumab, 3 mg/kg IV, once every 3 weeks for a total of 4 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <arm_group_label>Pembrolizumab Every 2 Weeks</arm_group_label>
    <arm_group_label>Pembrolizumab Every 3 Weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically-confirmed diagnosis of unresectable Stage III or metastatic melanoma
             not amenable to local therapy (excluding uveal or ocular melanoma)

          -  At least one measurable lesion

          -  No prior systemic treatment (excluding adjuvant or neoadjuvant therapy) for melanoma
             (first line) or one prior systemic treatment (excluding adjuvant or neoadjuvant
             therapy) for melanoma (second line)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Archived tissue sample or new biopsy sample

          -  Female participants of childbearing potential and male participants must agree to use
             effective contraception from Visit 1 to 120 days after the last dose of study drug;
             male participants must agree to use an adequate method of contraception starting with
             the first dose of study drug through 120 days after the last dose of study drug

        Exclusion criteria:

          -  Prior treatment with ipilimumab or other anti-cytotoxic T-Lymphocyte Antigen 4
             (CTLA-4) agent or any anti-programmed cell death (PD-1 or PD-L2) agent

          -  Chemotherapy, radioactive, or biological cancer therapy within four weeks prior to
             the first dose of study drug, or not recovered from adverse events caused by cancer
             therapeutics administered more than four weeks earlier

          -  Currently participating or has participated in a study of an investigational agent or
             using an investigational device within 30 days of the first dose of study drug

          -  Expected to require any other form of systemic or localized antineoplastic therapy
             while on study

          -  On any systemic steroid therapy within one week before the planned date for first
             dose of randomized treatment or on any other form of immunosuppressive medication

          -  History of a malignancy (other than the disease under treatment in the study) within
             5 years prior to first study drug administration, excluding adequately treated Stage
             1 or Stage 2 basal/squamous cell carcinoma of the skin, carcinoma in situ of the
             cervix or breast, or other in situ cancers.

          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis;
             participants with previously treated brain metastases are eligible

          -  Severe hypersensitivity reaction to treatment with another monoclonal antibody

          -  Active autoimmune disease or a documented history of autoimmune disease or syndrome
             that requires systemic steroids or immunosuppressive agents

          -  Active infection requiring systemic therapy

          -  Known history of Human Immunodeficiency Virus (HIV)

          -  Known history of or positive for Hepatitis B or C

          -  Known psychiatric or substance abuse disorder

          -  Regular user (including recreational use) of illicit drugs or had a recent history
             (within the last year) of substance abuse (including alcohol)

          -  Pregnant or breastfeeding, or expecting to conceive, or father children within the
             projected duration of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-1</keyword>
  <keyword>PD1</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
